To elucidate the dynamic effects of Capecitabine combined with PD-1 inhibitors treatment, we applied single-cell RNA sequencing (scRNA-seq) to longitudinally track CRC patients receiving capecitabine and nivolumab, a representative PD-1 inhibitor, combination therapy throughout the treatment course. Here, PDCD1 is linked to colorectal carcinoma.